At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 502 enrolled
Drug / intervention
Botulinum Toxin Type Bbiological
Likely dose
Botulinum Toxin Type B 5,000 Unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC·interventional·Posted Jun 20, 2008·Updated May 11, 2026
In Brief
A Phase 4 clinical trial evaluating Botulinum Toxin Type B for Cervical Dystonia. Completed, enrolled 502 participants.
Detailed Summary
Open label study to evaluate the safety and immunogenicity of MYOBLOC (Botulinum Toxin Type B) in adult patients with a clinical diagnosis of Cervical Dystonia (CD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Dystonia
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2001
Primary CompletionMay 2008
First PostedJun 2008
Study CompletionSep 2008
TodayJul 2026
First PostedJun 20, 2008
Enrollment StartJun 1, 2001
Primary CompletionMay 1, 2008
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 18.0 years ago
Interventions
Botulinum Toxin Type Bbiological
Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.